Calculating the predicted retinal thickness from spectral domain and time domain optical coherence tomography – comparison of different methods

Tan, Colin S.; Li, Kelvin Z.; Lim, Tock Han

doi:10.1007/s00417-014-2672-9

Cited by 10 publications

(5 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The study enrolled eyes with BCVA letter scores of 24-78 (approx. Snellen 20/320 to 20/32) and DME involving the foveal center with CRT greater than roughly 325 μm on modern SD-OCT (>250 μm on Zeiss Stratus with gender-specific cutoffs) [80] . The interim results after 1 year showed a mean gain that was +2.1 letters higher for aflibercept 2 mg than for ranibizumab 0.3 mg (the approved dose in the US, 0.5 mg is the approved dose in Europe) ( p = 0.03).…”

Section: Afliberceptmentioning

confidence: 99%

Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA)

García-Arumí²,

et al. 2017

View full text Add to dashboard Cite

Diabetic retinal disease is envisioned to become the plague of the coming decades with a steep increase of worldwide diabetes incidence followed by a substantial rise in retinal disease. Improvements in diagnostic and therapeutic care have to cope with this dilemma in a clinically and socioeconomically efficient manner. Laser treatment has found a less destructive competitor in pharmacological treatments. As a consequence of recent rigorous clinical trials, laser photocoagulation is no longer recommended for the treatment of diabetic macular edema (DME), and anti-vascular endothelial growth factor therapy has emerged as first-line therapy. Steroids have maintained a role in the management of chronically persistent DME. The paradigm shifts in therapy are accompanied by a substantial break-through in diagnostics. The following guidance for the management of DME has been composed from the best updated knowledge of leading experts in Europe and represents another volume in the series of EURETINA recommendations for the management of retinal disease.

show abstract

Section: Afliberceptmentioning

confidence: 99%

Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA)

García-Arumí²,

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Several studies have reported the results of comparing multiple OCT devices with each other,27–29 including methods of converting measurements from one model to those of another 30. In this study, the signal strength did not play a significant role in predicting macular thickness measurements.…”

Section: Discussionmentioning

confidence: 50%

Relationship between macular thickness measurement and signal strength using Stratus optical coherence tomography

Segal

Shapira

Gershoni

et al. 2016

OPTH

View full text Add to dashboard Cite

PurposeTo examine the relationship between signal strength and macular thickness as measured by Stratus optical coherence tomography (OCT)’s fast macular thickness protocol in healthy subjects.MethodsIn this prospective cross-sectional study 79 eyes of 42 healthy subjects were enrolled. The age, gender, and eye (right vs left) of each subject were recorded. The Stratus OCT fast macular thickness scan protocol was used and the macular thickness was measured with retinal thickness map analysis. Each eye was imaged at least six times to acquire images with signal strengths of 4, 5, 6, 7, 8, and 9 out of 10 via adjustment of the focusing knob. The OCT parameters included in the analysis were thickness in the central 1 mm and in the different quadrants in the 3-mm area.ResultsOverall 79 eyes of 42 patients with a mean age of 38.4±12.4 were included. There was no significant difference between the signal strength measurements obtained with different signal strengths in the central thickness (P=0.20). In the superior, nasal, inferior, and temporal quadrants, a signal strength of 8 demonstrated up to 3 µm thicker measurements than a signal strength of 5 (P<0.05). In general linear regression analysis, after accounting for age and gender, signal strength did not remain a significant predictor of thickness in any quadrant.ConclusionsWhen using fast map macular measurements, a signal strength of 5 is clinically as efficient as a signal strength of 8 in measuring macular thickness in all quadrants. Insisting on higher signal strength may not be necessary.

show abstract

“…The diagnosis of PCV and its differentiation from nAMD was performed using the diagnostic criteria described in the EVEREST and EVER EST II studies [6][7][8][9][10][11][12]. Central subfield retinal thickness (CSFT) was measured using the proprietary Heidelberg viewer software [13][14][15][16][17][18]. Trained graders screened each OCT B-scan for segmentation errors and manually adjusted these when errors were present.…”

Section: Methodsmentioning

confidence: 99%

Predictors of persistent disease activity following anti-VEGF loading dose for nAMD patients in Singapore: the DIALS study

et al. 2020

Self Cite

View full text Add to dashboard Cite

Background: To determine the frequency of persistent disease activity following 3 loading doses of anti-vascular endothelial growth factor (VEGF) agents, and the anatomic and demographic predictors of early persistent disease activity among patients with neovascular age-related macular degeneration (nAMD). Methods: In a retrospective real-world cohort study, 281 consecutive patients with nAMD were reviewed at baseline and after 3 anti-VEGF injections for pre-defined indicators of disease activity. Optical coherence tomography (OCT) features such as subretinal fluid, intraretinal cysts and intraretinal fluid were assessed by reading-center certified graders. Multiple logistic regression was performed on demographic and anatomic factors. Results: At month 3, 66.1% of patients had persistent disease activity. The best-corrected visual acuity (BCVA) improvement was 0.16 LogMAR for those with no disease activity compared to 0 for patients with persistent activity (p < 0.001). The significant risk factors for persistent activity at 3 months were male gender (odds ratio [OR] 0.54, 95% confidence interval [CI] 0.32-0.93, p = 0.025), intraretinal cysts at baseline (OR 2.95, 95% CI 1.67-5.20, p < 0.001) and subretinal fluid at baseline (OR 3.17, 95% CI 1.62-6.18, p = 0.002). At 3 months, 58% of patients had features of activity on OCT. Patients with intraretinal cysts and intraretinal fluid at baseline had worse BCVA at month 3 compared to patients without these OCT features (0.69 vs. 0.43, p < 0.001, and 0.62 vs. 0.43, p < 0.001, respectively). Conclusions: In a real-world study, 66.1% of nAMD patients have persistent disease activity after the initial loading dose, with poorer BCVA compared to those without. Baseline OCT features (intraretinal cysts and subretinal fluid) are useful predictors of persistent disease activity at month 3.

show abstract

Calculating the predicted retinal thickness from spectral domain and time domain optical coherence tomography – comparison of different methods

Cited by 10 publications

References 28 publications

Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA)

Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA)

Relationship between macular thickness measurement and signal strength using Stratus optical coherence tomography

Predictors of persistent disease activity following anti-VEGF loading dose for nAMD patients in Singapore: the DIALS study

Contact Info

Product

Resources

About